Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double Blind, Baseline Controlled Study Using Placebo as Reference for Assessing the Efficacy and Safety of Hydroxychloroquine Sulfate in Patients With Systemic Lupus Erythematosus or Cutaneous Lupus Erythematosus in the Presence of Active Lupus Erythematosus Specific Skin Lesion
Brief Summary: Primary Objective:

- To investigate the efficacy on skin manifestation of 16 weeks treatment of once daily regimen of hydroxychloroquine sulphate (HCQ) in patients with cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE) with active skin manifestation (CLASI \[Cutaneous Lupus Erythematosus Disease Area and Severity Index\] activity score is ≥4) concomitant treatment with or without corticosteroid.

Secondary Objectives:

* To evaluate the efficacy on skin manifestation and the safety of 16 weeks treatment of once daily regiment of HCQ versus placebo as the reference group in patients with CLE and SLE with active skin manifestation (CLASI activity score is ≥4) concomitant treatment with or without corticosteroid.
* To investigate the safety of 16 weeks treatment of once daily regiment of HCQ in patients with CLE and SLE with active skin manifestation concomitant treatment with or without corticosteroid.
* To investigate the safety and efficacy of 52 weeks long-term treatment of once daily regimen of HCQ in patients with CLE and SLE - To investigate the influence of the dose reduction of corticosteroid on CLE and SLE patients treated with HCQ concomitant with corticosteroid
* To investigate efficacy of once daily regimen of HCQ on systemic symptoms, musculoskeletal symptoms and immunological parameters in SLE patients.


Options:
A: Arm Label: HCQ; Type: ACTIVE_COMPARATOR; Interventions: Drug: hydroxychloroquine (Z0188) | Arm Label: Placebo; Type: OTHER; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: hydroxychloroquine (Z0188); Assigned to Arm(s): HCQ | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Biological: MEDI 545 | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Biological: MEDI-545 | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Biological: MEDI-545 | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Biological: MEDI-545 | Arm Label: 5; Type: ACTIVE_COMPARATOR; Interventions: Biological: MEDI-545 | Intervention Type: BIOLOGICAL; Name: MEDI-545; Assigned to Arm(s): 2 | Intervention Type: BIOLOGICAL; Name: MEDI 545; Assigned to Arm(s): 1 | Intervention Type: BIOLOGICAL; Name: MEDI-545; Assigned to Arm(s): 3 | Intervention Type: BIOLOGICAL; Name: MEDI-545; Assigned to Arm(s): 4 | Intervention Type: BIOLOGICAL; Name: MEDI-545; Assigned to Arm(s): 5
C: Arm Label: Abatacept + Prednisone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Abatacept, Drug: Prednisone | Arm Label: Placebo + Prednisone; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Prednisone | Arm Label: Abatacept; Type: EXPERIMENTAL; Interventions: Drug: Abatacept | Intervention Type: DRUG; Name: Abatacept; Assigned to Arm(s): Abatacept + Prednisone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + Prednisone | Intervention Type: DRUG; Name: Prednisone; Assigned to Arm(s): Abatacept + Prednisone, Placebo + Prednisone | Intervention Type: DRUG; Name: Abatacept; Assigned to Arm(s): Abatacept
D: Arm Label: Sifalimumab 200 milligram (mg); Type: EXPERIMENTAL; Interventions: Biological: Sifalimumab 200 mg | Arm Label: Sifalimumab 600 mg; Type: EXPERIMENTAL; Interventions: Biological: Sifalimumab 600 mg | Arm Label: Sifalimumab 1,200 mg; Type: EXPERIMENTAL; Interventions: Biological: Sifalimumab 1,200 mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: BIOLOGICAL; Name: Sifalimumab 200 mg; Assigned to Arm(s): Sifalimumab 200 milligram (mg) | Intervention Type: BIOLOGICAL; Name: Sifalimumab 600 mg; Assigned to Arm(s): Sifalimumab 600 mg | Intervention Type: BIOLOGICAL; Name: Sifalimumab 1,200 mg; Assigned to Arm(s): Sifalimumab 1,200 mg | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A